Bulk Inquiry
PD180970
- Soluble in DMSO
- MF: C21H15Cl2FN4O
- MW: 429.27
Description
More Information
| Parent CAS No. | 287204-45-9 |
|---|---|
| Chemical Name | 6-(2,6-Dichloro-phenyl)-2-(4-fluoro-3-methyl-phenylamino)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one |
| SMILES | N1C=C2C=C(C3C(Cl)=CC=CC=3Cl)C(=O)N(C)C2=NC=1NC1C=C(C)C(F)=CC=1 |
| MFCD | MFCD10565929 |
| InChi | InChI=1S/C21H15Cl2FN4O/c1-11-8-13(6-7-17(11)24)26-21-25-10-12-9-14(20(29)28(2)19(12)27-21)18-15(22)4-3-5-16(18)23/h3-10H,1-2H3,(H,25,26,27) |
| InChiKey | SLCFEJAMCRLYRG-UHFFFAOYSA-N |
| CID | 5311104 |
| Short Description | Bcr-Abl inhibitor |
References
- P La Rosée et al. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002, 62 (24), 7149-53.
- TS May. Gleevec: tailoring to fit. Drug Discovery Today (DDT), 2003, 8 (5), 188-189.
- M Huang et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002, 21(57), 8814-8816.
- JM Goldman, JV Melo. BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work? Acta Haematol 2008, 119, 212-217.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1392 | Dasatinib |
From $99.00 |
| 1394 | Imatinib mesylate |
From $66.00 |
| 1396 | Nilotinib |
From $55.00 |
| 1407 | SKI 606 |
From $82.50 |
| 1857 | AP 24534 |
From $77.00 |
| 1882 | GNF 2 |
From $121.00 |
| 2121 | INNO 406 |
From $93.50 |
| 2123 | Rebastinib |
From $121.00 |
| 2219 | AT 9283 |
From $99.00 |
| 2757 | Asciminib |
From $132.00 |
| 3168 | Nilotinib hydrochloride |
From $77.00 |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.